DURHAM, N.C. --(BUSINESS WIRE)--Sep. 6, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), a gene editing company utilizing its proprietary ARCUS® platform to develop in vivo gene editing therapies, today announced that members of management will participate in the following investor conferences in